New findings from Willis' latest Insurance Marketplace Realities report highlight favorable conditions for buyers, driven by abundant capital, advancing technology, and data-driven risk strategies. New findings from Willis' latest Insurance Marketplace Realities report highlight favorable conditions for buyers, driven by abundant capital, advancing technology, and data-driven risk strategies.

Silver rallied above $47.50 as gold/silver ratio tested multi-month lows.

Marsh & McLennan sub-unit Mercer launches AI-driven Workforce Insights and Aida to empower HR teams with data-backed decisions and global workforce intelligence.

LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO) securities between February 18, 2021 and June 24, 2025, inclusive (the “Class Period”).

LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired KinderCare Learning Companies, Inc. (“KinderCare” or the “Company”) (NYSE: KLC) common stock pursuant and/or traceable to the Company's October 2024 initial public offering (the “IPO”). IF YOU SUFFERED A LOSS ON YOUR KINDERCARE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

Ralph Lauren (RL) possesses solid growth attributes, which could help it handily outperform the market.

Cracker Barrel isn't done shaking things up.

CNBC's MacKenzie Sigalos reports on Google's move to embed Gemini AI across its home devices, as tech giants rush to make voice the next major interface for AI.

LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 21, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) securities between August 8, 2024 and August 14, 2025, inclusive (the “Class Period”).

Shares of USA Rare Earth (USAR) soared on Friday after its CEO said the supplier of rare earth magnets and minerals was in talks with the Trump White House.

LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”).

LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE) securities between July 15, 2025 and August 14, 2025, inclusive (the “Class Period”).

A Mizuho analyst thinks Wall Street is overreacting to the idea that Microsoft's cloud unit could lose OpenAI business down the road.

Chevron is selling a collection of pipeline assets in the Denver-Julesburg shale basin that are likely to fetch more than $2 billion, people familiar with the matter said.

ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK program and expanding pipeline support the investment thesis for IBRX.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholder.

Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late-stage pipeline and R&D investments offer long-term growth potential. Recent political developments reduce regulatory risks, and the company's diversified operations and pipeline help buffer near-term uncertainties.

Robinhood Markets, Inc. (HOOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

United Natural Foods (UNFI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Micron (MU) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.